Arcus Biosciences, Inc.
3928 Point Eden Way, Hayward, CA 94545
1800 Sierra Point Parkway, Brisbane, CA 94005
United States
184 articles with Arcus Biosciences, Inc.
-
Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences
3/8/2022
Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced several poster presentations at upcoming scientific conferences that support the ongoing investigation of its clinical and preclinical pipeline.
-
Arcus Biosciences Announces New Employment Inducement Grants - Feb 24, 2022
2/24/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 20,450 shares of the Company’s common stock at an exercise price per share of $30.01, which was the closing price on February 23, 2022, and restricted stock units to acquire a total of 10,225 shares of the Company’s common stock.
-
Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
2/23/2022
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and year ended December 31, 2021.
-
Arcus Biosciences to Participate in the Upcoming Investor Conferences - Feb 15, 2022
2/15/2022
Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate at the following upcoming investor conferences.
-
Arcus Biosciences Announces New Employment Inducement Grants - Feb 09, 2022
2/9/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 64,050 shares of the Company’s common stock at an exercise price per share of $30.30, which was the closing price on February 8, 2022, and restricted stock units to acquire a total of 2,025 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 25, 2022
1/25/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 38,850 shares of the Company’s common stock at an exercise price per share of $31.75, which was the closing price on January 24, 2022, and restricted stock units to acquire a total of 925 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 11, 2022
1/11/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 41,800 shares of the Company’s common stock at an exercise price per share of $37.56, which was the closing price on January 10, 2022.
-
Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
1/10/2022
Arcus Biosciences, Inc. today provided updates on clinical programs and key milestones anticipated in 2022.
-
Arcus Biosciences Announces New Employment Inducement Grants - Dec 24, 2021
12/24/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 23,400 shares of the Company’s common stock at an exercise price per share of $44.59, which was the closing price on December 23, 2021.
-
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-stage Programs and New Research Collaboration
12/21/2021
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced the closing of Gilead’s option exercises to three programs in Arcus’ clinical-stage portfolio and a new research collaboration between the two companies.
-
Arcus Biosciences Announces New Employment Inducement Grants - Dec 09, 2021
12/9/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 83,400 shares of the Company’s common stock at an exercise price per share of $44.17, which was the closing price on December 8, 2021.
-
Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
11/30/2021
Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., Ltd. announced that Taiho exercised its option for anti-TIGIT antibodies domvanalimab and AB308 from Arcus Biosciences, in Japan and certain other territories in Asia.
-
Arcus Biosciences Announces New Employment Inducement Grants - Nov 24, 2021
11/24/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 76,000 shares of the Company’s common stock at an exercise price per share of $48.47, which was the closing price on November 23, 2021.
-
Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
11/22/2021
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate in a fireside chat at the upcoming Evercore ISI HealthCONx 2021 Conference.
-
“I hope to thread the needle between pricing responsibly and achieving profitability," Jarrett said.
-
Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration
11/18/2021
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that Gilead has exercised its options to three programs in Arcus’s clinical-stage portfolio, including both anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat.
-
Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.
-
Arcus Biosciences Announces New Employment Inducement Grants - Nov 09, 2021
11/9/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 28,000 shares of the Company’s common stock at an exercise price per share of $34.74, which was the closing price on November 8, 2021.
-
Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab
11/8/2021
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2021 and provided an update on the ARC-7 study of domvanalimab.
-
Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights
11/2/2021
Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecule and combination medicines for people with cancer, announced that the company will report its financial results and a corporate update for the third quarter ended September 30, 2021 after the market closes on Monday, November 8, 2021.